NCT03366389 is a clinical trial in Irritable Bowel Syndrome, sponsored by Amir Abbasnezhad.

Who is sponsoring NCT03366389?

NCT03366389 is sponsored by Amir Abbasnezhad.

What condition does NCT03366389 study?

NCT03366389 studies Irritable Bowel Syndrome.

Is NCT03366389 still recruiting?

NCT03366389 is currently completed. Last updated 8 December 2017.

Last reviewed 2017-12-08 · How we verify

NCT03366389

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serum Levels of Apelin, Chemerin and Adiponectin Adipokines in Irritable Bowel Syndrome and Healthy Subjects

Completed Last updated 8 December 2017

What this trial tests

trial in Irritable Bowel Syndrome in 114 participants. Completed in 20 October 2017.

Timeline

7 June 2017

Primary endpoint
16 September 2017

20 October 2017

Quick facts

Lead sponsor	Amir Abbasnezhad
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114
Start date	7 June 2017
Primary completion	16 September 2017
Estimated completion	20 October 2017
Sites	1 location across Iran

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

Amir Abbasnezhad

Who can join

Adults 18 to 80, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this observational case-control study investigators aimed to assess the serum levels of adipokines such as Apelin, Chemerin and adiponectin in patients with irritable bowel syndrome (IBS), and compare it with healthy controls. Furthermore, investigators evaluated the possible correlation of these adipokines with IBS-QoL, IBSSS, GI symptoms and other clinical and psychological disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03366389 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amir Abbasnezhad
Last refreshed: 8 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing